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400 µg salbutamol and 80 µg ipratropium to assess the bron-
chodilator response at entry to the study, the mean increase 
in forced expiratory volume in 1 second (FEV1) was around 
200 mL with some patients showing increases in FEV1 of over 
500 mL2,3. As well as improving the FEV1, which is largely a 
measure of large and medium airway caliber, bronchodilators 
have significant effects on small airway function (which is of-
ten reflected in changes in forced vital capacity [FVC]) and on 
static and dynamic hyperinflation4-7.
Although the impact of COPD on patients’ functional capac-
ity and quality of life is affected by many factors not reflected 
in the degree of spirometric impairment, in large populations 
improvements in FEV1 correlate with reductions in breath-
lessness (measured by the transitional dyspnea index [TDI]), 
health status (measured by the St George’s Respiratory Ques-
tionnaire [SGRQ]), requirement for rescue medication use 
and the frequency of exacerbations8,9.
Main Text
Bronchodilators are the mainstay of the pharmacologi-
Introduction
Although chronic obstructive pulmonary disease (COPD) 
is defined by the presence of persistent respiratory symptoms 
and airflow limitation1 many people with COPD show a signif-
icant spirometric response to bronchodilators. For example, in 
both the Isolde and UPLIFT studies where patients were given 
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cal management of COPD and are recommended by the 
Global Obstructive Lung Disease Initiative (GOLD) as the 
preferred treatment for people with COPD1. Short acting 
bronchodilators, both β2-agonists and anti-muscarinics taken 
either as needed or regularly improve both breathlessness 
and lung function10 and greater effects are seen if drugs of 
both classes are combined11,12. However, many patients re-
main symptomatic despite the use of short acting drugs or 
have levels of symptoms that require treatment with more 
effective bronchodilators. The long acting anti-muscarinics 
(long-acting muscarinic antagonist [LAMA]) and long-acting 
β2 agonists (LABA) are both more effective than regular 
short-acting drugs and more convenient. Long-acting bron-
chodilator monotherapy reduces airflow limitation13-18 and 
dyspnoea13,14,18 and improves physical activity/exercise capac-
ity19-22, and health status13,14,16-18 as well as reducing the risk of 
exacerbations23.
Tiotropium bromide was the first LAMA to be approved 
for maintenance treatment of COPD24. It is available in two 
formulations: dry powder (18 mg once daily) delivered via 
the breath-actuated HandiHaler, and aqueous solution (5 mg, 
two puffs 2.5 mg once daily) delivered via the Respimat Soft 
Mist Inhaler. It is effective when administered once daily as it 
has a long elimination half-life compared with other available 
LAMAs (27–45 hours following inhalation compared with, for 
example, just 2–3 hours with aclidinium)25. Tiotropium has 
occupied a central role in the management of COPD for the 
last decade.
Olodaterol is a once-daily LABA that is highly selective with 
nearly full intrinsic activity at β2 receptors
26 and which has 
been shown to be effective at improving lung function over 
24 hours in patients with COPD27,28 and improving patient-
reported outcomes28.
Although long acting bronchodilators provide adequate 
control of symptoms for some patients, significant numbers of 
patients treated with long acting bronchodilator monotherapy 
continue to experience significant breathlessness. For exam-
ple, in a study of nearly 700 patients in both primary care and 
specialist centers in the United States over half had a modified 
Medical Research Council breathlessness score (mMRC) of 2 
or more despite treatment with a single long-acting broncho-
dilator29. 
LABAs and LAMAs act via different mechanisms; when 
used together in patients with COPD, they exert additional 
bronchodilating effects30-32. By targeting different receptors us-
ing an anti-muscarinic and a β agonist it is possible to increase 
the therapeutic benefits while minimizing dose-dependent 
side effects. The complementary pharmacological profiles of 
tiotropium and olodaterol make them ideal partners and data 
from studies using them in separate inhalers support the ben-
efits of combing them33,34. Following on from these studies, an 
extensive clinical trial programme (The TOviTO programme) 
has investigated the benefits of treatment with a combina-
tion of tiotropium and olodaterol administered via a single 
inhaler. Consolidating treatments into single devices ought to 
decrease the complexity of usage, improve compliance and 
improve outcomes, particularly if the device is a Respimat Soft 
Mist which is easy to use and gives good pulmonary deposi-
tion35,36. The TOviTO program consists of ten phase 3 stud-
ies evaluating the potential benefits and safety profile of the 
fixed-dose combination (FDC) of olodaterol and tiotropium 
through the Respimat inhaler. The program has studied over 
15,000 patients with moderate-to-very-severe COPD in more 
than 50 countries37.
The two replicate TONADO trials were randomised, 
double-blind, parallel-group, multicentre trials which com-
pared the efficacy and safety of tiotropium+olodaterol FDC 
administered via the Respimat device compared with the 
mono-components in patients with moderate to very severe 
COPD38. Current or ex-smokers aged 40 or more with at least 
a 10 pack year history of smoking and a post-bronchodilator 
FEV1 of less than 80% of their predicted value and a post-
bronchodilator FEV1/FVC less than 70% were randomized to 
receive tiotropium+olodaterol FDC 2.5/5 µg or 5/5 µg, tiotro-
pium 2.5 µg or 5 µg, or olodaterol 5 µg delivered once-daily 
via Respimat inhaler over 52 weeks. The primary end points 
were the FEV1 area under the curve from 0 to 3 hours (AUC0–3) 
response, trough FEV1 response and SGRQ total score at 24 
weeks. 
Both tiotropium+olodaterol fixed dose combinations sig-
nificantly improved FEV1 AUC0–3 and trough FEV1 response 
versus the mono-components in the two replicate studies. 
FEV1 AUC0–3 responses for tiotropium+olodaterol FDC 2.5/5 
µg, 5/5 µg, tiotropium 2.5 µg, 5 µg, and olodaterol 5 µg were 
241, 256, 148, 139, and 133 mL, respectively, in one study, 
and 256, 268, 125, 165, and 136 mL, respectively, in the other 
study. Improvements in the adjusted mean FEV1 AUC0–3 with 
tiotropium+olodaterol FDC 5/5 µg and 2.5/5 µg over the 
corresponding individual components in the individual stud-
ies and the combined analysis were statistically significant 
(p<0.0001 for all comparisons)38.
After 24 weeks, the pre-specified analysis of the adjusted 
mean SGRQ total score showed statistically significant im-
provements for tiotropium+olodaterol FDC 5/5 µg over corre-
sponding individual components (vs. olodaterol 5 µg: −1.693 
[0.553], p<0.01; vs. tiotropium 5 µg: −1.233 [0.551], p<0.05) but 
not for tiotropium+olodaterol FDC 2.5/5 µg versus the indi-
vidual components. An analysis of responder rates examining 
the proportion of patients who achieved a decrease in SGRQ 
total score by at least the minimum clinically important dif-
ference of 4.0 units was also performed. Over half of patients 
treated with the FDCs responded: the responder rates were 
57.5% for tiotropium+olodaterol 5/5 µg and 53.2% for 2.5/5. 
This compared to responder rates of 49.6%, 48.7%, and 44.8% 
for tiotropium 2.5 µg, 5 µg, and olodaterol 5 µg, respectively. 
The increases in the responder rates for tiotropium+olodaterol 
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FDC 5/5 µg over its individual components was statistically 
significant38.
There was also a statistically significant improvement in the 
key secondary end point of the Mahler TDI focal score at 24 
weeks in the combined data set for both tiotropium+olodaterol 
FDCs versus their mono-components (nominal p<0.05). 
Fifty-four point nine percentage of patients treated with 
tiotropium+olodaterol FDC 5/5 µg achieved the minimal clini-
cally important difference of 1 unit improvement in the TDI 
compared to 50.6% with 5 µg tiotropium and 48.2% with 5 µg 
olodaterol.
With both tiotropium+olodaterol FDC 5/5 µg and 2.5/5 
µg there was a reduction in adjusted weekly mean daily (24-
hour) rescue medication use compared to the monotherapy 
components throughout the 52-week treatment period. Such 
reductions in rescue medication are important indicators 
of whether patients notice a benefit from their maintenance 
therapy39.
The TONADO studies were not designed to examine the ef-
fects of tiotropium+olodaterol FDC on exacerbation rates but 
data on exacerbations were collected and there was a trend 
for improvement in exacerbations with the FDCs versus the 
monotherapy components. The incidence of adverse events 
was comparable between the FDCs and the mono-compo-
nents.
Post-hoc analysis of the TONADO studies showed tiotro-
pium+olodaterol FDC improved lung function over the 
mono-components in patients with GOLD 2 and 3–4 disease, 
irrespective of prior LAMA or LABA maintenance therapy 
and most comparisons between the FDCs and their respec-
tive mono-components were statistically significant (p<0.05)40. 
There was also no difference in the relative responses to 
tiotropium+olodaterol 5/5 µg compared to the mono-thera-
pies in different age groups41.
Adverse event incidence was generally balanced across all 
treatment groups, with the majority being mild to moderate in 
severity and the incidence of adverse events was comparable 
between the FDCs and the mono-components.
Because the TONADO studies ran for 52 weeks, it was 
considered unethical to include a placebo group, but it is im-
portant to be able to assess the effects of mono-therapy and 
the FDCs on patient reported outcomes (PRO) compared 
to placebo and the OTEMTO studies were designed to do 
this. These again comprised two randomized, double-blind, 
parallel-group, multicentre trials which compared the efficacy 
and safety of tiotropium+olodaterol FDC administered via the 
Respimat device compared with the mono-components and 
placebo over 12 weeks in patients with moderate to severe 
COPD42. The three primary end points, measured at 12 weeks, 
were SGRQ total score, and FEV1 AUC0–3 and trough FEV1 
changes from baseline.
In OTEMTO 1 and 2, after 12 weeks tiotropium+olodaterol 
5/5 µg significantly improved FEV1 AUC0–3 response com-
pared to placebo by 0.331 L and 0.299 L, respectively and 
improved trough FEV1 response by 0.162 L and 0.166 L com-
pared to placebo (p<0.0001).
Tiotropium+olodaterol 5/5 µg improved SGRQ total score 
at 12 weeks by 4.89 units and 4.56 units versus placebo 
(p<0.0001) in OTEMTO 1 and 2, respectively and the improve-
ment compared to tiotropium 5 µg was 2.49 units (p=0.0136) 
and 1.72 units (p=0.0780), respectively42. After 12 weeks of 
treatment 52% of patients receiving tiotropium+olodaterol 
5/5 µg were classed as SGRQ responders compared to 41% 
receiving tiotropium 5 µg (p<0.01) and 32% in the placebo 
group (p<0.0001)43.
Changes in TDI were assessed as a secondary endpoint. 
Tiotropium+olodaterol 5/5 µg improved TDI score at 12 
weeks by 2.05 units and 1.20 units versus placebo (p<0.0001) 
in OTEMTO 1 and 2. At week 12, 54% of patients receiving 
tiotropium+olodaterol 5/5 µg were classed as TDI responders 
compared to 41% receiving tiotropium (p<0.001) and 26% of 
patients receiving placebo (p<0.0001)43.
Post-hoc  analysis of the OTEMTO studies showed tiotro-
pium+olodaterol fixed dose combination improved lung func-
tion, SGRQ and TDI compared to tiotropium and placebo in 
patients with GOLD 2 and 3–4 disease44. There was also no 
difference in the relative responses to tiotropium+olodaterol 
5/5 µg compared to tiotropium and placebo in different 
age groups41. When analysed by baseline breathlessness 
assessed using the mMRC, the difference between SGRQ 
scores achieved by tiotropium+olodaterol 5/5 µg compared 
to tiotropium 5 µg was greatest in patients with an mMRC of 2 
or more compared to those with an mMRC less than 245. This 
shows that the greatest benefit of combination bronchodilator 
therapy is seen in the more symptomatic patients where it is 
most needed.
Multiple studies have assessed whether other LABA/LAMA 
combinations result in similar improvements in lung function, 
reductions in exacerbation rates, and achievement of minimal 
clinically important differences in TDI and SGRQ scores com-
pared to monotherapy46.
Clinically, it is important to know if there is additional bene-
fit of dual bronchodilator therapy in patients who have a good 
response to either LAMA or LABA monotherapy as well as 
those who do not. One study has examined the efficacy of dual 
bronchodilatation (umeclidinium+vilanterol 62.5/25 µg) in 
patients identified as responsive or non-responsive to mono-
bronchodilatation (umeclidinium 62.5 µg, vilanterol 25 µg)47. 
Umeclidinium+vilanterol significantly increased lung function 
versus umeclidinium in umeclidinium-responders and ver-
sus vilanterol in vilanterol-responders. In umeclidinium and 
vilanterol non-responders, lung function was still significantly 
increased by dual therapy, but by a smaller amount.
The CRYSTAL study examined directly switching from vari-
ous treatments to glycopyrronium (50 µg) or indacaterol+ 
glycopyrronium (110/50 µg) in terms of lung function and 
DMG Halpin
16 Tuberc Respir Dis 2018;81:13-18 www.e-trd.org
symptoms in symptomatic patients with moderate COPD48. 
This was a prospective, multicentre, 12-week, randomized, 
pragmatic, open-label trial designed to mimic clinical prac-
tice. Indacaterol+glycopyrronium significantly improved lung 
function and dyspnea after direct switch from LAMA or LABA. 
The effects of dual bronchodilator therapy on exercise 
capacity were examined in the TORRACTO study49. This 
was a randomized, double-blind, placebo-controlled study 
to determine the effect of 12-week treatment of inhaled 
tiotropium+olodaterol FDC at two different doses (2.5/5 µg 
and 5/5 µg) delivered by the Respimat inhaler on exercise 
endurance time during constant work rate cycle ergometry 
in 390 patients with COPD. The geometric mean endurance 
time during constant work rate cycle ergometry was 527.51 
seconds with tiotropium+olodaterol 5/5 µg (14% increase vs. 
placebo, p=0.021). Tiotropium+olodaterol 5/5 µg increased 
pre-exercise inspiratory capacity versus placebo at 12 weeks 
by 234 mL (p<0.0001) and at week 12, the slope of the inten-
sity of breathing discomfort (Borg scale) during exercise de-
creased with tiotropium+olodaterol 5/5 µg (p=0.060).
Tiotropium monotherapy is effective at reducing the 
risk of exacerbations23 and LABA/inhaled corticosteroid 
(ICS) was not more effective than tiotropium at prevent-
ing exacerbations in the INSPIRE study50. Recently, the 
FLAME study showed that dual bronchodilator therapy with 
indacaterol+glycopyrronium was more effective than LABA/
ICS at reducing exacerbation rates51. Currently, there are no 
data comparing tiotropium+olodaterol with tiotropium from 
studies with exacerbation rates as the primary outcome. The 
DYNAGITO study (registered as NCT02296138 at ClinicalTri-
als.gov) comparing the annualized rate of moderate-to-severe 
COPD exacerbations over 1 year in patients treated with 
tiotropium+olodaterol 5/5 µg or tiotropium 5 µg will provide 
these data. The study is still on going, but results are expected 
in late 2017 or early 2018.
Conclusion
The GOLD report emphasises the fact that bronchodila-
tors are central to the management of COPD1; however, many 
patients remain symptomatic despite mono-therapy with a 
LABA or LAMA. Dual bronchodilator therapy improves lung 
function and PRO compared to the mono-components, and 
reduces exacerbation rates compared to LABA/ICS.
Once-daily dosing of COPD therapy translates into signifi-
cantly higher adherence than other dosing frequencies, there-
by leading to reductions in healthcare resource utilization and 
cost52.
On the basis of the evidence for the effectiveness of dual 
bronchodilator therapy, the 2017 GOLD report recommends 
escalating to dual bronchodilator therapy in patients in group 
B (higher symptoms but low risk of exacerbations) if they have 
persistent breathlessness on monotherapy. It also states that 
for patients with severe breathlessness initial therapy with two 
bronchodilators may be considered.
The GOLD report also recommends that patients in group 
C (low symptoms but high risk of exacerbations) with persis-
tent exacerbations despite treatment with a LAMA may bene-
fit from escalation to dual bronchodilator therapy. For patients 
in group D (high symptoms and high risk of exacerbations) 
the GOLD report recommends starting treatment with dual 
bronchodilators.
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